Navigation Links
China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
Date:9/25/2008

-- Expects Revenue of $88 to $90 Million and Net Income of $27 to $28

Million

HARBIN, China, Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has increased its revenue and earnings guidance for the full-year 2008 period.

China Sky One Medical raised its full-year 2008 revenue guidance to $88- $90 million, up from its prior guidance of $81-$83 million, previously announced on August 12, 2008. In addition, the Company now estimates that full-year 2008 net income will be in the range of $27-$28 million, up from its previous estimate of $25.9-$26.6 million. China Sky One Medical expects 2008 gross margin to be approximately 77%. The Company's previous estimate for 2008 gross margin was 78.5%.

The increase in the Company's 2008 financial estimates is primarily due to strong results from an advertising campaign for its products that was launched in the second quarter, as well as expected contributions from acquisitions made in 2008. The Company recently started production at Peng Lai Jin Chuang Company ("Jin Chuang"), a newly established pharmaceutical company acquired in June. While Jin Chuang is expected to have a positive impact on 2008 results, it will take time for the Company to ramp up its manufacturing capacity and optimize efficiency in order to achieve large scale production. The Company is also increasing its level of R&D spending in the second half of 2008 to support its growing new product pipeline.

"Our business continues to perform well, and our recent acquisitions and the success of a large advertising campaign for our products that we launched in the second quarter are helping to drive our sales," said Mr. Yan-Qing Liu, Chairman, President, and CEO of China Sky One Medicine Inc. "We believe that we will see strong future growth as we continue our strategy of hiring direct territory managers and sales agents to strengthen our distribution channels, as well as increase our R&D to develop a wider range of new and exciting products."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-the- counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao, Board Secretary

Tel: +86-0451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Website: http://www.ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Website: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
2. tootoo.com: Chinas Farmers Welcome the New Trend of Organic Farming
3. China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification
4. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
5. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
6. China Biopharma Effects 1 for 100 Reverse Stock Split
7. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
8. China Yingxia International, Inc. Appoints New Vice President of Finance
9. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
10. China Biologic Products to Present at the SIG Beijing Management Summit
11. China Biologics Production Facility Renews GMP Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , Nov. 30, 2016   Merck , ... it has entered into a set of agreements with ... for Merck,s collection of genetic reagents such as CRISPR ... Evotec,s screening expertise offers an accelerated pathway to explore ... starts with the identification of new targets, a process ...
(Date:11/30/2016)... Woburn, MA (PRWEB) , ... November 30, 2016 ... ... broadband light sources for advanced technology applications, introduces the 5th generation, ultra-bright, Laser-Driven ... the highly successful Laser-Driven Light Source (LDLS™) technology, the EQ-77 offers higher radiance ...
(Date:11/30/2016)... , ... November 30, 2016 , ... On 28 November ... symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), ... public review, the names earlier proposed by the discoverers have been approved by the ...
(Date:11/30/2016)... ... November 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced that all five of its validated monoclonal antibody (mAb) therapeutic ... toxic, prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016 According to the new market research ... Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and ... the market is expected to grow from USD 10.74 Billion in 2015 ... between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
Breaking Biology News(10 mins):